Elimination of established tumors with nanodisc-based combination chemoimmunotherapy

Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting

(2017) Jie Tang et al.   Nanomedicine-Nanotechnology Biology and Medicine

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

ZnO-Based Nanoplatforms for Labeling and Treatment of Mouse Tumors without Detectable Toxic Side Effects

(2016) Dai-Xin Ye et al.   ACS Nano

High-Density Lipoproteins: Nature’s Multifunctional Nanoparticles

(2016) Rui Kuai et al.   ACS Nano

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin

(2016) Yue Yuan et al.   International Journal of Nanomedicine

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Designer vaccine nanodiscs for personalized cancer immunotherapy

(2016) Rui Kuai et al.   NATURE MATERIALS

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

(2016) D. Mathios et al.   Science Translational Medicine

Local and transient gene expression primes the liver to resist cancer metastasis

(2016) T. J. Goodwin et al.   Science Translational Medicine

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas

(2016) Chitra Subramanian et al.   SURGERY

A PEGylation-Free Biomimetic Porphyrin Nanoplatform for Personalized Cancer Theranostics

(2015) Liyang Cui et al.   ACS Nano

The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties

(2015) Anna Schwendeman et al.   JOURNAL OF LIPID RESEARCH

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

(2015) Sebastian Kreiter et al.   NATURE

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

(2015) Jonathan Rios-Doria et al.   NEOPLASIA

Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death

(2014) T. C. van der Sluis et al.   CLINICAL CANCER RESEARCH

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

(2014) Mahesh Yadav et al.   NATURE

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

HDL-targeted therapies: progress, failures and future

(2014) Bronwyn A. Kingwell et al.   NATURE REVIEWS DRUG DISCOVERY

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

(2014) Zineb Belcaid et al.   PLoS One

A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity

(2014) A. Maksimenko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy

(2013) Yuting Ma et al.   CANCER RESEARCH

Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity

(2013) T. H. Kang et al.   CANCER RESEARCH

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver

(2013) Yu Zhang et al.   CLINICAL & EXPERIMENTAL METASTASIS

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

(2013) Yuting Ma et al.   IMMUNITY

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses

(2012) Hyun-Il Cho et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity

(2012) Tomáš Etrych et al.   JOURNAL OF CONTROLLED RELEASE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk

(2009) M.T. Cooney et al.   ATHEROSCLEROSIS

Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis

(2009) Miguel A. Frias et al.   CARDIOVASCULAR RESEARCH

Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injection

(2009) J. Andrew MacKay et al.   NATURE MATERIALS

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE

In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells

(2008) Ken-ichi Ogawara et al.   JOURNAL OF CONTROLLED RELEASE